Taysha Gene Therapies (NASDAQ:TSHA) grants stock options to new employees under its 2023 Inducement Plan.The company's financial metrics indicate challenges, with a negative P/E ratio of -17.85 and a high price-to-sales ratio of 209.41.Despite financial hurdles, Taysha demonstrates a strong current ratio of 10.48, indicating robust short-term financial health.Taysha Gene Therapies, listed on Nasdaq as TSHA, is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic d ...